Publications by authors named "E Seyran"
Objective: To evaluate the effect of complete pathological response (pCR) on prognosis in patients with axillary lymph node-positive triple-negative breast cancer (TNBC) and the efficiency of adjuvant capecitabine.
Study Design: Analytical study. Place and Duration of the Study: University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, between March 2015 and December 2021.
Article Synopsis
- The study focused on elderly patients (65+) with extensive stage small cell lung cancer (SCLC), aiming to assess their clinicopathological characteristics, treatment approaches, and outcomes between 2009 and 2021.
- Out of 132 participants, the majority were male (89.4%) and 80.3% were diagnosed with extensive stage disease; first-line chemotherapy was administered to 65.2% of them, with the most common regimens being cisplatin+etoposide and carboplatin+etoposide.
- Treatment responses indicated that 4.7% had a complete response, 40.7% had a partial response, and 39.5% experienced progressive
Article Synopsis
- Cyclin-dependent kinase 4/6 inhibitors are new drugs that help treat certain types of metastatic breast cancer and can improve patient outcomes.
- A 56-year-old woman with breast cancer was treated with a drug called ribociclib and developed light patches on her skin (like vitiligo) after six treatment cycles.
- Although the skin changes aren't dangerous, they can be upsetting and make it harder for the patient to stick to her treatment plan.
Introduction: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are the new generation drugs that have been started to be used in our clinical practice recently. These drugs have been shown to have better progression-free survival compared to standard therapy in patients with hormone receptor-positive (HR) and human epidermal growth factor receptor 2 (HER-2)-negative breast cancer. The most common side effects of CDK 4-6 inhibitors are neutropenia, nausea, leukopenia, fatigue, and diarrhea.
View Article and Find Full Text PDFBackground: The relationship of the ABO blood group system with the immune response is known, but its relationship with immune checkpoint inhibitors (ICIs) has not been clearly investigated until now.
Objective: In this study, the relationship between different blood groups and nivolumab treatment response in patients with advanced malignant melanoma was investigated.
Methods: The data of patients who used nivolumab for advanced malignant melanoma between April 2018 and April 2021 were retrospectively reviewed.